Home Drug IndexClinical Monograph

Carbamazepine Uses, Dosage, Side Effects & Warnings | DrugsAtlas

Authoritative Clinical Reference

Therapeutic Class

Anticonvulsant

Subclass

Iminostilbene derivative

Speciality

Neurology

Schedule (India)

Schedule H

Routes

Oral

Formulations

Tablets (Immediate-Release): 100 mg, 200 mg, 400 mg
Controlled-Release (CR) Tablets: 200 mg, 400 mg
Oral Suspension: 100 mg/5 mL
Chewable Tablets: 100 mg

Note: Injectable formulation is NOT AVAILABLE in India for routine clinical use

Adult indications

INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

Primary Indications (Approved / Standard in India)

1. Partial Seizures (with or without secondary generalisation) and Generalised Tonic-Clonic Seizures

Adults — Monotherapy or Adjunctive Therapy:

Parameter	Recommendation
Starting dose	100–200 mg twice daily
Titration	Increase by 200 mg/day every 3–7 days as tolerated
Usual maintenance dose	800–1200 mg/day in 2–3 divided doses
Maximum dose	1600 mg/day

Clinical Notes:

Immediate-release formulations require twice or thrice daily dosing
CR formulations allow twice daily dosing with fewer peak-related adverse effects
Avoid abrupt withdrawal — taper gradually over 2–6 months
Therapeutic drug monitoring: target trough level 4–12 mcg/mL
Not effective for absence seizures — may worsen them

2. Trigeminal Neuralgia

Adults — First-line Pharmacotherapy:

Parameter	Recommendation
Starting dose	100 mg twice daily
Titration	Increase by 100–200 mg every 2–3 days based on pain response
Usual maintenance dose	400–800 mg/day in 2–3 divided doses
Maximum dose	1200 mg/day

Clinical Notes:

Use lowest effective dose to maintain remission
Periodic dose reduction attempts recommended to assess ongoing requirement
CR formulations preferred for sustained analgesia
Response typically seen within first week

3. Bipolar Affective Disorder — Acute Mania and Maintenance

Adults — Under Psychiatrist Supervision:

Parameter	Recommendation
Starting dose	200 mg twice daily
Titration	Increase by 200 mg every 3–5 days based on response and tolerability
Usual maintenance dose	600–1000 mg/day in divided doses
Maximum dose	1600 mg/day (specialist supervision required)

Clinical Notes:

Second-line agent after lithium and valproate in Indian psychiatric practice
CR formulations preferred to minimise peak-related CNS effects
Serum level monitoring helpful in non-responders
Monitor for drug interactions with other psychotropics

Secondary Indications – Adults Only (Off-label)

Indication	Dose	Duration	Supervision	Evidence Basis
Diabetic Peripheral Neuropathy — OFF-LABEL	Starting: 100 mg BD; Maintenance: 400–800 mg/day	4–12 weeks trial	Specialist only	Indian pain medicine practice; supportive clinical experience
Restless Leg Syndrome — OFF-LABEL	Starting: 100 mg at bedtime; Max: 400 mg/night	Short-term/intermittent	Specialist only	Limited RCT data; Indian neurology practice
Glossopharyngeal Neuralgia — OFF-LABEL	As per trigeminal neuralgia dosing	As required	Specialist only	Clinical experience; extrapolated from trigeminal neuralgia

Paediatric indications

PAEDIATRIC DOSING (Specialist Only)

Primary Indications: Partial Seizures, Generalised Tonic-Clonic Seizures

Age Restriction: Not recommended below 1 month of age except under specialist paediatric neurology supervision.

Age Group	Starting Dose	Titration	Usual Maintenance	Maximum Dose
1–6 months	5 mg/kg/day in 2–3 divided doses	Increase by 5 mg/kg/week	10–20 mg/kg/day	20 mg/kg/day
6 months – 1 year	5–10 mg/kg/day in 2–3 divided doses	Increase by 5 mg/kg every 5–7 days	10–20 mg/kg/day	35 mg/kg/day
1–5 years	10 mg/kg/day in 2–3 divided doses	Increase by 5 mg/kg every 5–7 days	15–25 mg/kg/day	35 mg/kg/day
6–12 years	10 mg/kg/day OR 100–200 mg/day	Increase by 100 mg every 3–5 days	20–30 mg/kg/day OR 400–800 mg/day	35 mg/kg/day OR 1000 mg/day
>12 years	100–200 mg twice daily	Increase by 200 mg every 3–5 days	800–1200 mg/day	1600 mg/day

Safety Monitoring:

Baseline and periodic CBC with differential count
LFTs at baseline and during first 3 months
Serum sodium monitoring (risk of SIADH)
Therapeutic drug monitoring if seizure control inadequate
CR formulations preferred in older children for better compliance

Secondary Indications – Paediatric (Off-label)

Indication	Notes
Trigeminal Neuralgia (rare in children) — OFF-LABEL	Dose as per weight-based seizure guidelines; specialist only
Paediatric Bipolar Disorder — OFF-LABEL	Child psychiatrist supervision mandatory; adolescent dosing applies; monitor for behavioural effects

Renal Adjustments

Renal Function	Recommendation
Mild impairment (eGFR 60–89)	No adjustment required
Moderate impairment (eGFR 30–59)	No initial adjustment; monitor for accumulation and adverse effects
Severe impairment (eGFR <30)	Use with caution; consider extending dosing interval; monitor drug levels
Haemodialysis	Not significantly removed; supplemental dosing generally not required post-dialysis
Peritoneal dialysis	No supplemental dosing required

Hepatic adjustment

Contraindications

Known hypersensitivity to carbamazepine, oxcarbazepine, or tricyclic antidepressants
History of bone marrow depression or blood dyscrasias
Acute intermittent porphyria
Concomitant or recent (within 14 days) MAO inhibitor therapy
Known HLA-B*1502 positivity (high risk of SJS/TEN) — screening recommended in at-risk populations
Atrioventricular conduction block (second or third degree)
Severe hepatic impairment
Concomitant use with voriconazole (loss of antifungal efficacy)

Cautions

History of hepatic disease or alcoholism — enhanced hepatotoxicity risk
Pre-existing hyponatraemia or conditions predisposing to SIADH
Cardiac disease, especially arrhythmias or heart failure
History of haematological reactions to other drugs
Mixed seizure disorders including absence seizures — may exacerbate absences
Elderly patients — increased sensitivity to CNS effects
History of psychosis or behavioural disturbance
Risk of suicidal ideation — monitor mood and behaviour
Patients of Asian ancestry (Han Chinese, Thai, Indian populations from certain regions) — increased HLA-B*1502 prevalence
Glaucoma — mild anticholinergic effects

Pregnancy

Parameter	Details
Risk category	Known teratogen; associated with neural tube defects, craniofacial abnormalities, developmental delay
Preferred alternatives	Lamotrigine, levetiracetam — preferred for epilepsy management during pregnancy
When may be used	Only if seizure control cannot be achieved with safer alternatives; monotherapy at lowest effective dose preferred
Monitoring required	High-dose folic acid (5 mg/day) from preconception through first trimester; targeted anomaly scan at 18–20 weeks; maternal serum AFP; serial fetal growth monitoring
Neonatal concerns	Monitor neonate for withdrawal symptoms and vitamin K deficiency bleeding

Lactation

Parameter	Details
Compatibility	Generally compatible with breastfeeding; benefits usually outweigh risks
Drug levels in milk	Moderate (infant receives approximately 5–10% of maternal weight-adjusted dose)
Preferred alternatives	Lamotrigine, levetiracetam also compatible; valproate carries higher concerns
Infant monitoring	Observe for sedation, poor feeding, jaundice, hepatic dysfunction; monitor infant weight gain

Elderly

Parameter	Recommendation
Starting dose	100 mg once or twice daily
Titration	Very gradual — increase by 100 mg every 5–7 days
Special risks	Increased CNS depression, ataxia, falls, confusion; hyponatraemia more common; cardiac conduction effects; drug interactions with polypharmacy
Monitoring	Serum sodium at baseline and periodically; gait assessment; cognitive monitoring

Major drug interactions

Drug/Class	Mechanism/Effect	Recommendation
MAO inhibitors	Serotonergic crisis risk; unpredictable toxicity	Contraindicated — 14-day washout required
Voriconazole	Carbamazepine induces metabolism → subtherapeutic antifungal levels	Contraindicated — avoid combination
Clarithromycin, erythromycin	Strong CYP3A4 inhibition → carbamazepine toxicity	Avoid if possible; if unavoidable, reduce carbamazepine dose and monitor levels
Valproate	Increases carbamazepine-10,11-epoxide (active/toxic metabolite)	Monitor for toxicity even with "normal" carbamazepine levels
Phenytoin, phenobarbital	Mutual enzyme induction → reduced efficacy of both	Monitor levels of both drugs; dose adjustment often needed
Warfarin	CYP induction → reduced warfarin effect → decreased INR	Monitor INR closely; warfarin dose increase often required
Combined oral contraceptives	Reduced contraceptive efficacy	Advise alternative or additional contraception
Doxycycline	Reduced doxycycline half-life and efficacy	Consider alternative antibiotic or higher doxycycline dose

Moderate drug interactions

Drug/Class	Effect	Recommendation
Isoniazid	Inhibits carbamazepine metabolism; additive hepatotoxicity	Monitor LFTs frequently; watch for carbamazepine toxicity
Diltiazem, verapamil	Moderate CYP3A4 inhibition → raised carbamazepine levels	Monitor for toxicity; may need dose reduction
Fluoxetine, fluvoxamine	CYP inhibition → raised carbamazepine levels	Monitor for CNS toxicity; consider dose adjustment
Cimetidine	Inhibits carbamazepine metabolism	Prefer ranitidine or PPIs; monitor if used together
Theophylline	Induced metabolism → reduced theophylline levels	Monitor theophylline levels; dose increase may be needed
Lithium	Increased risk of neurotoxicity without changing lithium levels	Monitor for tremor, ataxia, confusion; use cautiously
Rifampicin	Enzyme induction → reduced carbamazepine efficacy	Monitor seizure control; may need dose increase
Methadone	Induced metabolism → reduced methadone effect	Monitor for opioid withdrawal; methadone dose increase may be needed

Common Adverse effects

Dizziness and ataxia (especially during initiation and dose increases)
Nausea and vomiting
Diplopia and blurred vision
Drowsiness and fatigue
Headache
Dry mouth
Mild leucopenia (often transient and benign)
Mild transaminase elevation
Skin rash (non-serious; discontinue if concerning features)
Hyponatraemia (SIADH)

Serious Adverse effects

Adverse Effect	Clinical Action
Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis	Immediate discontinuation and hospitalisation — especially in HLA-B*1502 positive patients
Aplastic anaemia / Agranulocytosis	Discontinue immediately; urgent haematology referral
DRESS syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms)	Discontinue; supportive care; may require corticosteroids
Hepatic failure	Discontinue; liver function monitoring; specialist referral
Cardiac arrhythmias / AV block	ECG monitoring; discontinue if significant conduction abnormalities
Severe hyponatraemia	May require fluid restriction; discontinuation if severe or symptomatic
Suicidal ideation / behavioural changes	Close psychiatric monitoring; consider drug discontinuation
Pancreatitis	Discontinue; supportive management
Multi-organ hypersensitivity	Immediate discontinuation; hospitalisation

Monitoring requirements

Baseline:

Complete blood count with differential
Liver function tests (AST, ALT, ALP, bilirubin)
Renal function (serum creatinine, electrolytes)
Serum sodium
HLA-B*1502 screening in high-risk populations (North-East India, patients of Han Chinese/Thai ancestry)
ECG in patients with cardiac history or elderly
Pregnancy test in women of childbearing age

After Initiation / Dose Change:

Serum carbamazepine level after steady state achieved (5–7 days)
CBC and LFTs at 2 weeks, 4 weeks, then 3 months
Serum sodium at 2–4 weeks
Clinical assessment for rash, CNS effects

Long-term Monitoring:

CBC and LFTs every 6–12 months
Serum sodium every 3–6 months (more frequently in elderly)
Annual thyroid function tests
Bone health assessment with long-term use (vitamin D, calcium, DEXA if indicated)
Seizure diary review
Psychiatric assessment for mood and behaviour

Brands in India

Immediate-Release Tablets:

Tegretol (Novartis)
Zeptol (Sun Pharma)
Mazetol (Intas)
Carbatol (Sanofi)
Zen (Mankind)
Carzep (Cipla)

Controlled-Release Tablets:

Tegretol CR (Novartis)
Zeptol CR (Sun Pharma)
Mazetol CR (Intas)

Oral Suspension:

Tegretol Suspension (Novartis)
Zeptol Syrup (Sun Pharma)

Chewable Tablets:

Tegretol Chewable (Novartis)

Price range (INR)

Formulation	Approximate Price
Tablets 100 mg (per tablet)	₹1.50–₹3.00
Tablets 200 mg (per tablet)	₹2.00–₹5.00
Tablets 400 mg (per tablet)	₹4.00–₹8.00
CR Tablets 200 mg (per tablet)	₹5.00–₹8.00
CR Tablets 400 mg (per tablet)	₹8.00–₹12.00
Oral Suspension 100 mL	₹40–₹75

Included in NLEM 2022 for epilepsy
NPPA price ceiling applicable for scheduled formulations
Generic options widely available at lower cost

Clinical pearls

Slow titration is essential — most CNS and GI adverse effects are dose-related and occur during initiation; gradual uptitration improves tolerability significantly
HLA-B*1502 testing before initiation — strongly recommended in patients from North-East India and those of Han Chinese, Thai, or South-East Asian ancestry to identify high-risk individuals for SJS/TEN
Brand consistency matters — bioavailability varies between manufacturers; avoid switching brands once seizure control achieved; if switch necessary, monitor closely
Avoid in absence and myoclonic seizures — carbamazepine may worsen these seizure types; contraindicated in juvenile myoclonic epilepsy
Autoinduction phenomenon — carbamazepine induces its own metabolism over 2–4 weeks; initial dose may need upward adjustment after this period to maintain therapeutic levels
Hyponatraemia in elderly — carbamazepine-induced SIADH is common in patients over 65 years; routine sodium monitoring essential
Contraceptive counselling mandatory — enzyme induction significantly reduces efficacy of hormonal contraceptives; advise barrier methods or IUD

Version

RxIndia v1.0 — 05 Jun 2025

Reference

- CDSCO approved product inserts
- Indian Pharmacopoeia
- National List of Essential Medicines (NLEM) 2022
- API Textbook of Medicine
- AIIMS Treatment Guidelines — Epilepsy Management
- ICMR Guidelines on Epilepsy
- IAP Paediatric Drug Formulary
- Indian Psychiatric Society treatment protocols
- Indian Epilepsy Society recommendations
- Goodman & Gilman's The Pharmacological Basis of Therapeutics (supportive)

⚖️

Clinical Responsibility

This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.

Content Feedback

Is this information helpful?

Help us improve our clinical database for the medical community.

RxIndia

Loading clinical data...